Rang	Name	Position
1	Mr. Benjamin Halladay M.B.A.	Chief Financial Officer
2	Mr. John B. Harlow Jr.	Chief Commercial Officer
3	Mr. Glenn P. Brame	Chief Technical Operations Officer
4	Mr. Benjamin O. Looker J.D.	Corporate Secretary, Chief Legal & Corporate Affairs Officer
5	Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications
6	Ms. Betty Jean Swartz	Chief Business Officer
7	Dr. Stephen Pinkosky	Vice President of Drug Discovery of Early Pre-Clinical Development

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	BlackRock Inc	6,93%	56,77 Mio. USD
2	Wasatch Advisors LP	6,12%	50,15 Mio. USD
3	Vanguard Group Inc	5,80%	47,53 Mio. USD
4	Two Seas Capital LP	4,42%	36,24 Mio. USD
5	Orbimed Advisors, LLC	4,10%	33,61 Mio. USD
6	Vanguard Capital Management, LLC	4,05%	33,18 Mio. USD
7	Two Sigma Investments LLC	3,67%	30,08 Mio. USD
8	Marshall Wace Asset Management Ltd	2,75%	22,50 Mio. USD
9	State Street Corp	2,74%	22,44 Mio. USD
10	D. E. Shaw & Co LP	2,54%	20,80 Mio. USD
11	Geode Capital Management, LLC	2,31%	18,94 Mio. USD
12	AIGH Capital Management, LLC	1,71%	13,99 Mio. USD
13	UBS Group AG	1,67%	13,65 Mio. USD
14	Armistice Capital, LLC	1,53%	12,50 Mio. USD
15	Penderfund Capital Management Ltd	1,51%	12,38 Mio. USD
16	Nuveen, LLC	1,40%	11,49 Mio. USD
17	Vanguard Portfolio Management, LLC	1,37%	11,23 Mio. USD
18	Two Sigma Advisers, LLC	1,36%	11,15 Mio. USD
19	Privium Fund Management B.V.	1,28%	10,49 Mio. USD
20	Morgan Stanley - Brokerage Accounts	1,06%	8,70 Mio. USD